Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9499634B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2013 |
| Grant date | Nov 22, 2016 |
| Priority date | — |
| Expiry date | Feb 25, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/64
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing clone can be identified at a success frequency that permits for screening of tens of clones rather than thousands. The asymmetric antibodies are produced at a high titre and with a high level of purity with no contaminating homodimer antibodies following protein A purification with a step yield of near 100%. Typical downstream purification processes employ standard hydrophobic interaction chromatography (HIC) and/or cation exchange (CEX) resins and the antibody is stable within a wide dynamic range of buffer pH (4-8) and within the requirements for manufacturing antibodies for pre-clinical and clinical applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.